Tech | infostain

Insights on mRNA Delivery Systems and Lipid Nanoparticle Research

mRNA is a temporary genetic messenger that provides instructions for producing proteins within cells. Unlike approaches that permanently modify DNA, mRNA-based technologies are designed to use these instructions for . . .

Learn About How mRNA Therapeutics Deliver Genetic Instructions

Messenger RNA, commonly called mRNA, is a molecule that carries instructions from DNA to cellular machinery responsible for making proteins. mRNA therapeutics use this natural biological process by introducing . . .

Guide to mRNA Vaccine Technology and Modern Medical Research

Messenger RNA is a naturally occurring molecule that carries instructions from DNA to ribosomes, where proteins are produced. mRNA therapeutics use this biological process by introducing laboratory produced mRNA . . .

Explore ADC Therapeutics Technology and Cancer Drug Development

ADC Therapeutics focuses on antibody drug conjugates, commonly known as ADCs, which are medicines designed to combine targeted recognition with potent anticancer activity. An ADC generally contains an antibody, . . .

Read About ADC Therapeutics Research in Lymphoma Treatment

ADC Therapeutics focuses its lymphoma research on antibody drug conjugates, which are medicines designed to combine the targeting ability of an antibody with a cancer killing payload. Its principal . . .

Insights on ADC Therapeutics Pipeline and Oncology Research

ADC Therapeutics focuses its oncology research on antibody drug conjugates, which are designed to deliver potent therapeutic payloads to cancer cells through targeted antibodies. Its leading medicine, ZYNLONTA, is . . .

Learn About Antibody Drug Conjugates and ADC Therapeutics

Antibody drug conjugates, commonly called ADCs, are medicines designed by combining three main components: a targeted antibody, a linker, and a therapeutic drug known as a payload. The antibody . . .

Guide to ZYNLONTA Research and ADC Therapeutics Development

ZYNLONTA, also known by its generic name loncastuximab tesirine-lpyl, is a CD19-directed antibody drug conjugate. The U.S. Food and Drug Administration originally approved it in April 2021 for adults . . .

Explore ADC Therapeutics and Targeted Cancer Treatment Research

ADC Therapeutics is a biotechnology company focused on developing antibody drug conjugates, commonly known as ADCs. These therapies combine an antibody that recognizes a specific target with a cytotoxic . . .

Read About ADC Therapeutics ZYNLONTA and Clinical Development

ZYNLONTA, whose active ingredient is loncastuximab tesirine-lpyl, is an antibody drug conjugate that targets CD19, a protein expressed on many B cells. The medicine combines an antibody component with . . .